Multi event Drug Recall Enforcement Report Class II voluntary initiated by Lupin Pharmaceuticals Inc., originally initiated on 10-23-2024 for the product Ramipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 68180-590-01), and c) 500 count (NDC 68180-590-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India The product was recalled due to cgmp deviations: active pharmaceutical ingredient was sourced from an unapproved vendor. The product was distributed nationwide and the recall is currently ongoing.
Recall Enforcement Reports
Recall Number |
Recall Initiation Date |
Report Date |
Recall Classification |
Quantity |
Product Description |
Recall Reason |
Status |
D-0053-2025 | 10-23-2024 | 11-27-2024 | Class II | 146,322 bottles | Ramipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 68180-590-01), and c) 500 count (NDC 68180-590-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India | CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor | Ongoing |
D-0054-2025 | 10-23-2024 | 11-27-2024 | Class II | 357,414 bottles | Ramipril Capsules USP 10 mg, a) 90 count (NDC 68180-591-09), b) 100 count NDC 68180-591-01), and c) 500 count (NDC 68180-591-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India | CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor | Ongoing |
D-0052-2025 | 10-23-2024 | 11-27-2024 | Class II | 112,770 bottles | Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India | CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor | Ongoing |
Recalled Products